ENSG00000223804 and neoplasm: Alternatively, changes in pathways that compensate for the loss of Polθ activity could conceivably cause resistance, as could molecular changes that compensate for dysfunction in the tumour suppressor being synthetic lethal targeted by a Polθi (e.g. BRCA1, BRCA2).